| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 6 | |
| #2 | China | 3 | |
| #3 | WIPO (World Intellectual Property Organization) | 3 | |
| #4 | EPO (European Patent Office) | 2 | |
| #5 | Canada | 1 | |
| #6 | Japan | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Peptides | |
| #3 | Medical preparations | |
| #4 | Special acyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Nicodemus Christopher F | 15 |
| #2 | Madiyalakan Ragupathy | 14 |
| #3 | Hollingsworth Michael A | 3 |
| #4 | Penichet Manuel L | 1 |
| #5 | Helguera Gustavo | 1 |
| #6 | Daniels Tracy R | 1 |
| #7 | Schultes Birgit C | 1 |
| #8 | Ragupathy Madiyalakan | 1 |
| #9 | Rodriguez Jose A | 1 |
| #10 | Christopher F Nicodemus | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2018141054A1 | Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant | |
| EP3357509A1 | Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant | |
| CN107405410A | The method that increase anticancer delivers to target | |
| CN106794246A | Specific for tumour antigen antibody and TLR3 stimulate to strengthen the performance that cancer therapy is disturbed in checkpoint | |
| EP2331130A2 | Ige antibodies for the treatment of cancer |